Efficacy of zolmitriptan at early time-points for the acute treatment of migraine and treatment of recurrence: A randomised, placebo-controlled trial

CNS Drugs

Volumn 13, Issue 3, 2000, Pages 215-226

  Ryan Jr , Robert E ^a   Diamond, Seymour ^b   Giammarco, Rose A M ^c   Aurora, Sheena K ^d   Reed, Ronald C ^e   Fletcher, Pamela E ^f  

^a Ryan Headache Center   (United States)

^b DIAMOND HEADACHE CLINIC   (United States)

^c Practice of Neurology   (Canada)

^d HENRY FORD HOSPITAL   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ZOLMITRIPTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT OUTCOME;

EID: 0034066654     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200013030-00007     Document Type: Article

References (28)

1. 1. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors. JAMA 1992; 267: 64-9
2. 2. Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology 1994; 44 Suppl. 4: SI7-23
3. 3. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1-96
4. 4. Smith R. Impact of migraine on the family. Headache 1998; 36: 423-6
5. 5. Clarke CE, MacMillan L, Sondhi S, et al. Economic and social impact of migraine. Q J Med 1996; 89: 77-84
6. 6. Silberstein SD. Migraine symptoms: survey of 500 self-reported migraineurs [abstract]. Headache 1995; 35: 286
7. 7. Goadsby PJ, Olesen J. Increasing the options for effective migraine management. Neurology 1997; 48 Suppl. 3: S1-3
8. 8. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology 1997; 49: 1210-8
9. 9. Solomon GD, Cady RK, Klapper JA, et al. Clinical efficacy and tolerability of 2.5mg zolmitripian for the acute treatment of migraine. Neurology 1997; 49: 1219-25
10. 10. International 311C90 Long-term Study Group. The long-term tolerabilily and efficacy of oral zolmitriptan ('Zomig', 311C90) in the acute treatment of migraine. Headache 1998; 38: 173-83
11. 11. Tepper SJ, Donnan GA, Dowson AJ, et al. A long-term study to maximize migraine relief with zolmitriptan. Curr Med Res Opin 1999; 15: 254-71
12. 12. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991; 31: 295-9
13. 13. Pfaffenrath V, Cunin G, Sjonell G, et al. Efficacy and safety of sumatriptan tablets (25mg, 50mg, and 100mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184-90
14. 14. Lines C, Visser WH, Vandormael K, et al. Rizatriptan 5mg versus sumatriptan 50mg in the acute treatment of migraine [abstract and poster]. 39th Annual Scientific Meeting of the American Association for the Study of Headache: 1997 Jun 19-22; New York. Headache 1997; 37: 319-20
15. 15. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998; 51: 773-81
16. 16. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5mg and 10mg versus sumatriptan 25mg and 50mg in migraine. Headache 1998; 38: 737-47
17. 17. Sargent J, Kirchner JR, Davis R, et al. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 1995; 45 Suppl. 7: S10-4
18. 18. Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs sumutriptan in the acute treatment of migraine: a placebo-controlled, dose-ranging study. Arch Neurol 1996; 53: 1132-7
19. 19. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998; 38: 748-55
20. 20. Bomhof M, Paz J, Legg N, et al. Comparison of rizatriptan 10mg vs. naratriptan 2.5mg in migraine. Eur Neurol 1999; 42: 173-9
21. 21. Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997; 17: 647-51
22. 22. Teall J, Tuchman M, Cutler N, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache 1998; 38: 281-7
23. 23. MacGregor A. Management of migraine in general practice. Prescriber 1998; 9: 49,53-54,58
24. 24. Block GA, Kramer M-S, Matzura-Wolfe D, et al. Long-term exposure to rizatriptan 5mg and 10mg oral tablets [abstract and poster]. 39th Annual Scienlific Meeting of the American Association for the Study of Headache: 1997 Jun 19-22; New York. Headache 1997; 37: 302
25. 25. Rapoport AM, Visser WH, Cutler NR, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine altacks with subcutaneous sumatriptan. Neurology 1995; 45: 1505-9
26. 26. Scott RJ, Aitchison WRC, Baker PR, et al. Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice. Q J Med 1996; 89: 613-22
27. 27. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrence. Cephalalgia 1994; 14: 330-8
28. IB/ID agonist. Cephalalgia 1997; 17 Suppl. 18: 41-52